| Business Summary | | Urologix,
Inc.
was
organized
to
research,
develop,
manufacture
and
market
innovative
devices
for
the
treatment
of
benign
prostatic
hyperplasia
(BPH)
and
other
urological
disorders.
The
Company's
Targis
System
is
a
non-surgical,
catheter-based
treatment
for
BPH
that
is
better
than
medication
and
less
invasive
than
surgery.
The
Targis
System
was
developed
to
be
the
therapy
of
choice
for
patients
for
whom
drugs
have
failed
but
who
wish
to
avoid
choosing
surgery.
The
Targis
System
utilizes
a
proprietary
microwave
technology,
delivered
through
a
flexible
catheter
that
precisely
targets
energy
into
the
diseased
area
of
the
prostate
to
a
temperature
sufficient
to
cause
cell
death,
while
simultaneously
cooling
and
protecting
the
pain
sensitive
urethral
tissue. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Urologix,
Inc.
develops,
manufactures
and
markets
minimally
invasive
medical
devices
for
the
treatment
of
urological
diseases.
The
Company's
product,
called
Targis
System,
is
designed
to
treat
Benign
Prostatic
Hyperplasia.
For
the
fiscal
year
ended
6/30/01,
sales
rose
88%
to
$15.3
million.
Net
loss
fell
28%
to
$5.1
million.
Revenues
reflect
higher
demand
for
Targis
and
Prostatron
systems
from
urologists.
Net
loss
reflects
costs
related
to
the
expansion
of
sales
force. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
5,691;
after
tax
earnings
were
-854. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Mitchell Dann, 40 Chairman | -- | Michael Selzer, Jr., 48 Pres,
CEO, Director | $291K | Ronald Blasewitz, 51 Sr.
VP, COO | 150K | Christopher Geyen, 29 VP,
CFO, Sec., Treasurer | 136K | Kirsten Doerfert, 44 VP,
Marketing | -- | Dollar amounts are as of 30-June-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|